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For several decades, regulatory testing
schemes for genetic damage have been stan-
dardized where the tests being utilized exam-
ined mutations and structural and numerical
chromosomal damage. This has served the
genetic toxicity community well when most of
the substances being tested were amenable to
such assays. The outcome from this testing is
usually a dichotomous (yes/no) evaluation of
test results, and in many instances, the infor-
mation is only used to determine whether a
substance has carcinogenic potential or not.
Over the same time period, mechanisms and
modes of action (MOAs) that elucidate a wid-
er range of genomic damage involved in
many adverse health outcomes have been rec-
ognized. In addition, a paradigm shift in
applied genetic toxicology is moving the field
toward a more quantitative dose-response
analysis and point-of-departure (PoD) determi-
nation with a focus on risks to exposed
humans. This is directing emphasis on genomic
damage that is likely to induce changes asso-
ciated with a variety of adverse health out-
comes. This paradigm shift is moving the
testing emphasis for genetic damage from a
hazard identification only evaluation to a
more comprehensive risk assessment approach
that provides more insightful information for
decision makers regarding the potential risk of
genetic damage to exposed humans. To
enable this broader context for examining
genetic damage, a next generation testing
strategy needs to take into account a broader,
more flexible approach to testing, and ulti-
mately modeling, of genomic damage as it
relates to human exposure. This is consistent
with the larger risk assessment context being
used in regulatory decision making. As pre-
sented here, this flexible approach for examin-
ing genomic damage focuses on testing for
relevant genomic effects that can be, as best
as possible, associated with an adverse health
effect. The most desired linkage for risk to
humans would be changes in loci associated
with human diseases, whether in somatic or
germ cells. The outline of a flexible approach
and associated considerations are presented in
a series of nine steps, some of which can
occur in parallel, which was developed
through a collaborative effort by leading
genetic toxicologists from academia, govern-
ment, and industry through the International
Life Sciences Institute (ILSI) Health and Environ-
mental Sciences Institute (HESI) Genetic Toxi-
cology Technical Committee (GTTC). The
ultimate goal is to provide quantitative data to
model the potential risk levels of substances,
which induce genomic damage contributing to
human adverse health outcomes. Any good
risk assessment begins with asking the appro-
priate risk management questions in a plan-
ning and scoping effort. This step sets up the
problem to be addressed (e.g., broadly, does
genomic damage need to be addressed, and
if so, how to proceed). The next two steps
assemble what is known about the problem by
building a knowledge base about the sub-
stance of concern and developing a rational
biological argument for why testing for geno-
mic damage is needed or not. By focusing on
the risk management problem and potential
genomic damage of concern, the next step of
assay(s) selection takes place. The work-up of
the problem during the earlier steps provides
the insight to which assays would most likely
produce the most meaningful data. This discus-
sion does not detail the wide range of geno-
mic damage tests available, but points to
types of testing systems that can be very use-
ful. Once the assays are performed and ana-
lyzed, the relevant data sets are selected for
modeling potential risk. From this point on, the
data are evaluated and modeled as they are
for any other toxicology endpoint. Any
observed genomic damage/effects (or genetic
event(s)) can be modeled via a dose-response
analysis and determination of an estimated
PoD. When a quantitative risk analysis is
needed for decision making, a parallel expo-
sure assessment effort is performed (exposure
assessment is not detailed here as this is not
the focus of this discussion; guidelines for this
assessment exist elsewhere). Then the PoD for
genomic damage is used with the exposure
information to develop risk estimations (e.g.,
using reference dose (RfD), margin of expo-
sure (MOE) approaches) in a risk characteriza-
tion and presented to risk managers for
informing decision making. This approach is
applicable now for incorporating genomic
damage results into the decision-making pro-
cess for assessing potential adverse outcomes
in chemically exposed humans and is consis-
tent with the ILSI HESI Risk Assessment in the
21st Century (RISK21) roadmap. This applies
to any substance to which humans are
exposed, including pharmaceuticals, agricultur-
al products, food additives, and other chemi-
cals. It is time for regulatory bodies to
incorporate the broader knowledge and
insights provided by genomic damage results
into the assessments of risk to more fully
understand the potential of adverse outcomes
in chemically exposed humans, thus improving
the assessment of risk due to genomic dam-
age. The historical use of genomic damage
data as a yes/no gateway for possible cancer
risk has been too narrowly focused in risk
assessment. The recent advances in assaying
for and understanding genomic damage,
including eventually epigenetic alterations,
obviously add a greater wealth of information
for determining potential risk to humans. Regu-
latory bodies need to embrace this paradigm
shift from hazard identification to quantitative
analysis and to incorporate the wider range of
genomic damage in their assessments of risk
to humans. The quantitative analyses and
methodologies discussed here can be readily
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applied to genomic damage testing results now.
Indeed, with the passage of the recent update to
the Toxic Substances Control Act (TSCA) in the
US, the new generation testing strategy for geno-
mic damage described here provides a regulato-
ry agency (here the US Environmental Protection
Agency (EPA), but suitable for others) a golden
opportunity to reexamine the way it addresses
risk-based genomic damage testing (including
hazard identification and exposure). Environ.
Mol. Mutagen. 00:000–000, 2016. VC 2016
The Authors. Environmental and Molecular
Mutagenesis Published by Wiley Periodicals, Inc.
Key words: genetic toxicology; risk assessment; exposure assessment; integrated testing strategy;
mutagenicity
INTRODUCTION
Testing for mutagenicity endpoints has been in practice
for over half a century with both in vitro and in vivo test
systems [for review see Cimino, 2006]. For the past sever-
al decades, a fairly standardized approach has been in
place for regulatory testing of substances for mutagenic
activity [e.g., see Dearfield et al., 1991; M€uller et al.,
1999; Eastmond et al., 2009]. The standard battery incor-
porates a bacterial mutagenicity test (“Ames” assay), usual-
ly one or two in vitro mammalian cell tests selected for
gene mutations (e.g., mouse lymphoma assay) and for
chromosome damage (e.g., micronucleus or chromosomal
aberration test), and one or more in vivo tests depending
on the results of the in vitro tests and the regulatory guid-
ance being followed. This standard battery has served the
regulatory purposes well when, during the early years of
mutagenicity testing, most of the substances being tested
were generally electrophilic and therefore able to damage
DNA. In more recent times, because of smarter structural
design during development of new substances to avoid
reactive moieties in the molecule, many substances are not
typical “direct” DNA-damaging substances. Some of these
non-electrophilic substances may induce damage to the
genetic material, but not be readily detected in the standard
battery. It is clear now that many other types of genomic
alterations exist besides gene mutation, clastogenicity, and
aneugenic events that can impact human health. Thus, it is
time to address this wider range of alterations and the
related perturbation of toxicity pathways. For genetic toxic-
ity testing to evolve and take into account emerging tech-
nologies and recent scientific knowledge, a different
approach is needed to capture the potential of a substance
for inducing functional genomic alterations. Due to the
broader scale of genomic alterations and functional out-
comes, we must clearly move away from a “one-size-fits-
all” standard test battery approach and develop a more
flexible approach that also includes an understanding of
the underlying mechanisms affecting adverse outcomes.
Historically, the genetic toxicology testing community
has based its testing strategy on a simple yes/no paradigm
in which the main question was whether the substance
being tested has genomic damaging capability (i.e., haz-
ard identification). The next generation approach described
in the following discussion takes into account many aspects
of accepted risk assessment practices (e.g., planning and
scoping, quantitative analysis of dose-response results,
exposure assessment) that the genetic toxicology testing
community has not usually embraced. This entails greater
emphasis on estimating the potential risk of a substance if
and when people are exposed rather than applying genotox-
icity testing data only for hazard identification. Adhering
more closely to these risk assessment practices will provide
more informative data for risk management of exposures to
substances that have potential to damage the genome. Many
risk guidances and documents have been written over the
years and this discussion will refer to those materials for
fuller descriptions rather than provide extensive detail here,
except to highlight how genomic damage testing fits into
these practices.
Further, the more flexible approach will allow for
assessment of a greater diversity of genomic damage than
is currently being measured. Initially, cancer was the end-
point for which most genotoxicity assays were used to
predict hazard. However, there is now much greater
knowledge of the contribution or association of genomic
damage and other endpoints (e.g., adverse outcome path-
ways, epigenetics) with various health outcomes besides
cancer [Milic et al., 2015]. This widening focus includes
heritable genetic damage (germ cell risk), aging (accumu-
lation of genetic damage) [Moskalev et al., 2012; Wolters
and Schumacher, 2013], cardiovascular disease [Uryga
et al., 2016], and the specific contribution of different
types of genomic damage (e.g., specific mutations in
tumor suppressor genes and oncogenes) to cancer risk and
the various stages of cancer (e.g., [Dycaico et al., 1996;
Pottenger et al., 2014]). The use of a more flexible
approach allows deployment of new tools, such as high-
throughput assays and advanced sequencing approaches,
in ways that permit integration of the new knowledge on
both genomic endpoints and the potential health conse-
quences of genomic interactions.
To provide direction as to what a “next generation”
approach might look like, the Genetic Toxicology Techni-
cal Committee (GTTC) of the International Life Sciences
Institute (ILSI) Health and Environmental Sciences Insti-
tute (HESI) formed a work group to formulate a flexible
strategy. This work group had various discussions on this
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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flexible approach, including workshops at the 6th Interna-
tional Workshop on Genotoxicity Testing (IWGT) in
Iguassu, Brazil, on October 31, 2013 and at the GTTC
Annual Meeting in Washington DC, on April 13, 2015.
The outcomes from these discussions are the basis for the
present manuscript. Since this topic directly relates to oth-
er GTTC work groups addressing quantitative analysis,
germ cell testing, and emerging technologies, output and
results from discussions held in those work groups are
also taken into account.
Work group members generally agreed that important
aspects (discussed in the following sections in more
detail) to be considered and/or incorporated when design-
ing a next generation approach include: (i) advances in
mechanistic understanding of toxicity of a given sub-
stance; (ii) the human relevance of the mechanism(s)
involved; (iii) the need to expand from genetic to geno-
mic alterations, and to include other endpoints of genomic
damage associated with human diseases besides cancer;
(iv) the need for a flexible, efficient, and animal-sparing
approach to assess more substances, with greater speed
and accuracy; (v) the need to consider likely human expo-
sure; (vi) the need to take into account potentially suscep-
tible populations and different life stages in humans; and
(vii) to contextualize the data in terms of risk rather than
simply identifying a hazard. These challenges may be
met by using pathway-based approaches to characterize
the processes by which toxic substances induce adverse
health effects. The National Research Council (NRC) pre-
sented the concept of “toxicity pathways” in their report
on “Toxicity Testing in the 21st Century: A Vision and a
Strategy” [NRC, 2007]. In this report, toxicity pathways
are defined as normal signaling processes that lead to
adverse health effects if significantly perturbed. To orga-
nize and communicate the available knowledge on toxici-
ty pathways in a structured and consistent manner, the
concept of Adverse Outcome Pathways (AOPs) has been
proposed [Ankley et al., 2010]. An AOP depicts, in a lin-
ear way, linkages between chemically induced adverse
effects at various levels of biological organization as they
progress from a molecular initiating event (MIE) to an
adverse outcome (AO) [Ankley et al., 2010]. AOPs are
important tools to enhance the implementation of path-
way- and mechanistic-based approaches in risk assess-
ment [Villeneuve et al., 2014], and this has been
recognized by the Organisation for Economic Co-
operation and Development (OECD) [OECD, 2013].
In the following sections, we describe a stepwise
approach for a next generation strategy to assess the risk
of genomic damage as a result of exposure to chemical
substances. Since there are many variables and potential
pathways, the strategy discussed here does not provide a
specific decision-tree type of approach (i.e., “a one-size
fits all” approach), but rather introduces and discusses the
many factors that should be taken into account when
designing a rational testing scheme for any particular sub-
stance of interest. The applicability of this framework is
also highly relevant to the evolving regulatory context;
for example, with the recent update to the Toxic Substan-
ces Control Act (TSCA), the U.S. Environmental Protec-
tion Agency (EPA) will utilize risk-based evaluations to
determine safety and priorities [see USEPA, 2016 for
details of updated act].
APPROACH
We propose a general defined approach to provide a
useful and consistent strategy for examining the genomic
damage a substance may induce when a person is
exposed (Fig. 1). It will produce the information required
to determine the extent of public health risk that may
occur; if there is unacceptable risk, the information may
help to direct possible mitigation actions. The approach
outlined here consists of steps that ultimately provide
knowledge about the risk posed by genomic damage and
estimates of risk. Such an approach offers consistency
while providing a framework for flexibility in the specific
actions and testing that can be applied for specific sub-
stances or combination of substances. Overall, this
approach is consistent with the approach developed in the
ILSI HESI RISK21 project [Embry et al., 2014].
Fig.1. Strategy for examining genomic damage
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Planning and Scoping
Before attempting to test a substance for genomic dam-
age, it is necessary to establish the reason(s) for the test-
ing; this is the planning and scoping process. From the
risk assessment literature, this upfront discussion and
thought process is a critical step before embarking on
subsequent actions [NRC, 2009]. The planning and scop-
ing process defines the purpose and scope of the testing
and focuses on the issues and specific approach(es)
involved in the testing [for fuller description see USEPA,
2000—Chapter 2; USEPA, 2014a]. Planning and scoping
provide the opportunity to define what is expected to be
covered in the risk assessment and to explain the pur-
poses for which the risk assessment information will be
used.
The main purpose of planning and scoping is to decide
whether testing for genomic damage is necessary and
what particular approach(es) should be considered. If test-
ing is required for regulatory purposes, then the relevant
regulation(s) must be considered. Alternatively, testing
may be necessary as a result of public concern, based on
some scientific findings that need clarification, insights
for further development of a substance, or other factors.
Human relevance must be addressed, including identify-
ing what exposures to people need to be considered. For
example, if there is low or no anticipated exposure by
any route, the need for any further testing beyond the
minimal data/information set should be carefully evaluat-
ed. Most importantly, a listing of risk management ques-
tions is created that focuses on why testing is necessary
and what the path forward should be, i.e., does testing fit
with management goals and policies and what is the con-
text for any testing. This is the “fit for purpose” approach
the NRC discusses as critical for efficient and effective
risk assessment efforts to support risk management
decision making [NRC, 2009].
Exposure information can provide an important per-
spective to define or to refine a test plan, and to help
ensure appropriate data on hazard and dose response are
available to support risk assessment. These data can
inform testing of key elements and thus contribute to
resource optimization, including the 3 “Rs” of animal
welfare (Replace, Reduce, Refine). While it is unlikely
that reliable quantitative exposure data will be available
upfront for test plan development of early stage or new
substance entities, these substances nonetheless have a
target application in focus, which could lend itself to
qualitative or semi-quantitative (e.g., levels of concern,
ranking) approaches as an early stage exposure
assessment.
If the exposure assessment is used as a screening
device for setting priorities, the emphasis is probably
more on the comparative risk levels, perhaps with the risk
estimates falling into broad categories (e.g., semi-
quantitative categories such as high, medium, and low)
[USEPA, 1992]. Developing a semi-quantitative scheme
leading to categorizing (“binning”) the likely exposure
scenarios, based on a combination of target application
arenas and structural information, e.g., quantitative struc-
ture–activity relationship (QSAR) or read-across, can pro-
vide a general direction toward the appropriate base set
of data to assess toxicity to the genome. For example,
Health Canada developed a strategy based on three identi-
fied “levels of concern” (LOC); this approach relies on a
combination of application-type and structural information
[HPB, 1993]. Similarly, the International Council of
Chemical Associations (ICCA) has proposed such a semi-
quantitative scheme based on expected potential for expo-
sure drawn from an application-type approach [ICCA,
2011]. Additionally, not only the extent of exposure
would be important, but the nature of the susceptible
groups in the population that may be exposed would be
just as important to consider and may influence the level
of concern.
In concert with the high-throughput toxicity testing
efforts of ToxCast and related programs, there is an EPA-
led effort to develop high-throughput exposure assessment
approaches, i.e., ExpoCast, to provide an early perspec-
tive on exposure and risk. A framework is proposed to
extend efforts beyond simple models, such as USEtox
(UNEP-SETAC toxicity) [Rosenbaum et al., 2008, 2011]
and RAIDAR (Risk Assessment IDentification And Rank-
ing) [Arnot et al., 2006], to more complex ones that
incorporate Bayesian approaches and reverse toxicoki-
netics to support exposure estimates based on National
Health and Nutrition Examination Survey (NHANES)
biomonitoring data [Wambaugh et al., 2013]. Extensive
data analysis revealed that this information was helpful in
prioritizing substances according to their relative risk to
induce adverse human health effects, and that such early
incorporation of exposure information can help determine
priorities for additional data collection.
Categorization of exposure scenarios could be applied
in order to define an initial base set of genetic toxicity
data. Of course, a base set is exactly that—only the
base—and as such may require additional data to ade-
quately inform risk assessment. Qualitative categories to
inform development of a base set of genetic toxicity test-
ing data are listed in Table I. Such an approach could be
further refined by establishing a sliding scale from low or
no “discernable” concern to higher levels of concern, and
by establishing limits for top concentrations/doses tested
in the toxicity assays, which would then further rely on
the collection of dose-response data. For example, for a
substance anticipated to have a wide-spread human expo-
sure, it may be necessary to examine the genetic toxicity
at multiple dose levels that are above and below the
human exposure levels to determine a point-of-departure
(PoD) based on dose-response modeling [Gollapudi et al.,
Environmental and Molecular Mutagenesis. DOI 10.1002/em
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2013; Johnson et al., 2014]. For a substance with minimal
exposure potential, a small series of high-throughput tests,
or if the regulatory authority desires much more certainty,
a small scale in vivo test at a limit dose, for example,
1,000 times greater than the anticipated human exposure
(and likely with a reduced animal number), may provide
adequate information for prioritization of the substance
for any further testing.
The strategy for the selection of limit concentrations
for in vitro studies was extensively addressed by the ICH
(International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use) S2R1 guidance document for human phar-
maceuticals [ICH, 2011] and by OECD Guidance docu-
ments [OECD, 2014a,b] for other test substances. These
strategies were aimed at increasing the specificity of the
test systems while optimizing the sensitivity to detect
potential genotoxic agents. Both ICH and OECD recom-
mend that for relatively insoluble test substances, the lim-
it concentration should be the lowest concentration with
minimal amount of precipitate. For freely soluble human
pharmaceuticals that are not cytotoxic, the ICH recom-
mended a limit concentration of 1 mM or 0.5 mg/mL,
whichever is lower. This recommendation was based on a
survey of clinical exposures to known human pharmaceu-
ticals and the systemic levels achievable in pre-clinical
laboratory animal studies. The OECD, on the other hand,
recommended a limit concentration of 10 mM or 2 mg/
mL, whichever is lower, to represent the best balance
between molarity and mg/mL and to cover substances
with a wide range of molecular weights. In the case of
test substances that are mixtures or of unknown composi-
tion, the OECD recommends a limit concentration of
5 mg/mL. While these recommendations are useful as
default upper limits, it is recommended that all available
information on a test substance (e.g., toxicokinetics and
metabolic saturation) is taken into consideration to select
a scientifically justifiable upper limit dose or concentra-
tions for testing.
Planned case studies to further develop a flexible
approach for the assessment of genomic damage will,
amongst others, be used to define base sets of genetic tox-
icity data for the various categories of exposure. These
case studies will cover different regulations; depending
on the particular regulatory requirements, base sets, if
needed at all, may therefore differ in composition.
Logistically, planning and scoping also outlines the
testing approach and its follow-up. Aspects such as who
will do the testing, predicted costs, and what milestones
and timeframes are involved are delineated. Planning and
scoping also identifies which stakeholders need to be
involved and what coordination may be necessary to
work with the stakeholders. Additional actions including
incorporating peer review and information quality analy-
sis should be part of the planning and scoping discussion.
Options regarding how to move forward with any risk
management actions, such as mitigations, should be pre-
sented as possibilities at this stage in advance of testing
and before results are reviewed. A question that might be
addressed at the end of planning and scoping is whether
there is enough information already available that a deci-
sion not to test might be an option. This question may be
asked again after building the knowledge base.
Build the Knowledge Base
Usually occurring concurrently with planning and scop-
ing is the effort to assemble what is known already about
the substance(s) being considered, i.e., building the
knowledge base on the substance of interest. There are
many data streams to examine and from which to extract
TABLE I.Exposure-Based Qualitative Categories to Inform Development of a Base Set of Genetic Toxicity Testing Data
Exposure Group Exposed Population Exposure-based Category and Expected Actions
Closed system/Isolated
intermediate– Industrial use only
Industrial/Production
workers only
Minimal/Low exposure; Expect reliable use of recommended Per-
sonal Protective Equipment (PPE)
Incorporation into or
onto matrix–Industrial use
Industrial workers only Low exposure; Expect reliable use of recommended PPE
Non-dispersive/Professional use Professional workers only Moderate exposure potential; Expect reliable use of recommended
PPE; Dose-response data/determination of PoDs provides per-
spective on potential for risk
Wide dispersive Environmental/Human
populations
Potential for wide exposure in general population; Industrial chemi-
cals, drugs, etc. which are discharged into the environment via
waste streams during manufacture or end of life after disposal;
No expectations vis-a-vis PPE; Dose-response data/determination
of PoDs provides perspective on potential for risk; Will likely
conduct risk assessment
Wide dispersive/Consumer use Consumers Potential for wide/high exposure in general population; Chemicals
such as drugs, devices, and food-based substances for consumer
use; No expectations vis-a-vis PPE; Dose-response data/determi-
nation of PoDs provides perspective on potential for risk; Will
likely conduct risk assessment
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any extant information, especially because in many
instances substances are being developed or considered
for some particular purpose(s) and therefore will likely
fall under some regulatory scrutiny. Figure 2 presents
some of the pertinent information that can be assembled.
It should be noted that existing data do not necessarily
need to be exclusively from genetic toxicity tests. This
allows the development of a broader range of knowledge
of the substance in the absence of apical test data or in
vitro testing data.
The resulting knowledge base provides input to the
planning and scoping considerations and provides prelimi-
nary information in relation to the risk management ques-
tions. It may even provide some of the initial answers to
those questions. Just as important as identifying what
information and data are available, this effort identifies
information needs and data gaps that may be important in
learning and understanding more about the substance’s
potential to cause genomic damage. Ultimately, building
the knowledge base helps shape the future direction in
deciding what testing is needed.
Intended Uses, Biological Targets, Physico-Chemical
Characteristics
The intended use can provide information regarding the
potential routes of exposure and likely extent of exposure.
Further, if a substance is being developed for a specific
purpose, its intended target can focus where the potential
biological activity may occur (i.e., tissue, cellular, or
intracellular targets). This, together with the physico-
chemical characteristics (e.g., volatility, pH, solubility),
can provide insight into what potential reactions may
occur. This could provide ideas regarding what tests
would be most appropriate to assess that activity (e.g.,
electrophilic reactions with DNA sites).
(Quantitative) Structure^Activity Relationships and Analogue
Searching (Read-across)
(Quantitative) Structure–Activity Relationships
[(Q)SAR] and analogue information provide predictions
of potential chemical toxic activity. With the available
(Q)SAR software systems and their models, one can
distinguish those methods that make a quantitative predic-
tion (QSAR), e.g., a quantitative probability of an adverse
effect or a maximum recommended daily dose of a phar-
maceutical, and those non-quantitative SAR models that
aim to indicate the potential of a substance to exert a tox-
icological effect. (Q)SAR models can be used for both
screening and prioritization. Such a prioritization compo-
nent could complement in vitro testing, wherein the theo-
retical models are used to indicate the type of in vitro
testing required to establish a more detailed (quantitative)
indication of the potential human health hazard of a spe-
cific substance.
In many instances, the parent substance is the sub-
stance of interest for testing. However, consideration
should also be given, when possible, to potential metabo-
lites that may occur which also need to be tested (phar-
maceuticals; food additives), particularly if they have
structural alerts for possible toxicity that may not be pre-
sent in the parent substance. There are various in silico
methods to predict metabolism, by applying metabolism
simulators such as META (MultiCASE Inc.), METEOR
(Lhasa Ltd.), or the metabolism simulators included in
the freely available OECD QSAR Toolbox. A complicat-
ing factor in these metabolism simulators is the absence
of a (good) indication of the relevance (expected abun-
dance) of individual predicted metabolites.
The application of most available (Q)SAR models is
restricted to organic substances of small to moderate size.
Models covering inorganic substances are very rare
(although some are now emerging, e.g., aiming at
explaining the toxicity of inorganic nanomaterials), and
most (Q)SAR models do not cover organo-metallic sub-
stances as their chemistry is often very different from
“normal” organic chemistry. The areas in human health
toxicology where the largest numbers and most successful
applications of (Q)SARs can be found (e.g., mutagenicity,
sensitization) are mechanistically related to some form of
reactivity, which can be seen as an inherent property
related to chemical structure. Some (Q)SAR software sys-
tems now available are described in Table II.
Although for certain toxicity endpoints and specific
classes of substances (Q)SAR models have been sug-
gested as full replacements for in vitro or even in vivo
testing; in general, such predictions are rarely accepted
for regulatory purposes. One exception exists for predic-
tions of bacterial mutagenicity under the very specific
conditions defined in ICH M7 for impurities in pharma-
ceuticals [ICH, 2014]. Other regulatory programs have
accepted QSAR and/or read-across for impurities which
cannot be synthesized/purified in sufficient quantity for
use as a test article, generally handled on a case by case
basis. (Q)SAR prediction is accepted in the REACH
(Registration, Evaluation, Authorisation, and Restriction
of Chemicals) regulatory framework as an input into a
Weight of Evidence, where model prediction, for example
Fig. 2. Available information/data.
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TABLE II.Examples of Existing (Quantitative) Structure–Activity Relationship ((Q)SAR) Software Systems (Listed in Alphabet-
ical Order by Software Name)
CASE Ultra
(MultiCASE, Inc.)
 CASE Ultra is a commercial (Q)SAR software system that provides the two complimentary (Q)SAR methodologies
(statistics-based QSAR and expert rule-based SAR) currently suggested for evaluating the potential toxicity of
chemicals
 CASE Ultra provides test results, identifying alerts, their statistical parameters and explaining the way they are
used to arrive at the final prediction call
Derek Nexus and Sarah
Nexus (Lhasa Limited)
 Derek Nexus is a commercial human expert-based SAR software system that evaluates the potential toxicity of exist-
ing or prospective chemicals by identifying substructures in substances that are known to be related to a specific
type of chemistry related to toxicity based on previously acquired human experience
 Derek Nexus covers many specific toxicity endpoints, but with varying depth of coverage for each (e.g., it contains
over 400 alerts related to bacterial mutagenicity), but only 13 alerts are currently identified that are related to
reproductive toxicology (fertility and developmental toxicity)
 Derek Nexus makes decisions about which chemicals are likely to have ‘more favorable’ toxic profiles when the user does
not have as much experimental information as desired about the toxicity of each chemical
 Sarah Nexus processes submitted chemical structures by fragmentation, after which the fragments are reviewed for
activity versus inactivity; the Sarah Nexus model then arranges those ’interesting’ fragments into a network of
hypotheses (or nodes) and relevant hypotheses are used to inform an overall prediction of toxicity
 The Sarah Nexus prediction includes an overall conclusion about the toxicity in a structure, confidence rating in
that prediction, as well as supporting examples
Model Applier
(Leadscope, Inc.)
 Model Applier is a commercial (Q)SAR software system that provides the two complimentary (Q)SAR methodologies
(statistics-based QSAR and expert rule-based SAR) currently suggested for evaluating the potential toxicity of
chemicals
 Model Applier QSAR models are built using the structural feature and properties as descriptors. The models
encode the relationship between these descriptors and the toxicity endpoint, such as the results of the bacterial
mutagenesis assay. The modeling technique used to generate these models is referred to as partial logistic
regression
 When a statistical-based prediction is made on a new chemical, the same structural features and properties in the
model are calculated for the test compounds; these descriptors are then used with the models to calculate a proba-
bility of a positive result
 The Leadscope genetox expert alerts are based on well-defined mutagenicity structural alerts from the literature,
validated against a large database of over 7,000 chemicals with Salmonella mutagenicity data (the reference set);
alongside this list of alerts, deactivating factors as well as active subclasses (which represent possible cohorts of
concern) are encoded
 A positive expert-based prediction is made where one or more alerts are present with no defined deactivating factor
 In addition, the software determines whether the test compound is similar enough to known classes of chemicals
such that it is not trying to extrapolate to areas of chemistry the system has never seen
 A positive prediction is only made when the compound is within this applicability domain; a negative prediction is




 Symmetry is a commercial statistical-based QSAR software system that applies advanced machine learning techni-
ques to a variety of structural features and physicochemical properties of small molecules to provide quality pre-
dictions about biological effects
 Available Symmetry algorithms include binary classification for active/inactive data sets, meta-classifiers to
achieve consensus predictions for sets of binary models and multi-label learning that yields ranking and probabilis-
tic estimates of the possible outcomes
 Symmetry uses models based on data sets comprised of small molecules and associated biological properties
Toolbox (OECD)  The OECD Toolbox is a freely available eclectic collection of contributed (Q)SAR models of varying quality and
usefulness
 Toolbox tries to identify similar substances for which toxicity data are available, and that subsequently allows the user
to apply read-across, define a grouping approach (with or without trend line), and/or apply existing simple QSARs
 Toolbox relies on existing models and information and does not introduce new models, but allows the user to
apply existing knowledge/models
 Numerous theoretical models are available for the prediction of toxicity, differing in their applicability domains
(some are meant for a narrowly defined class of substances, e.g., substituted phenols, while others aim at predic-
tions, e.g., “low molecular weight organic chemicals” in general)
VEGA (freeware)  VEGA uses statistical modeling, but supplies the user with “analogue” data
 VEGA is a culmination of models from several European Union Framework projects aimed at development of
QSARs for toxicity
 Endpoints covered by VEGA models include mutagenicity, carcinogenicity, skin sensitization and developmental
toxicity
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together with in vitro information, can be sufficiently con-
vincing to replace (waive) in vivo testing [REACH,
2007].
Analogue searching (read-across) is a methodology that
relies on identifying similar chemicals to the one of inter-
est, not only in terms of (overall) chemical structure, but
specifically also with a similar functionality which is
related to the toxicological effect of interest. Other prop-
erties that require similarity for a successful read-across
are physico-chemical properties and/or bioavailability,
and when metabolism could play a role in activation or
detoxification, a similar (expected) metabolic profile. If a
sufficiently similar substance can be found for which tox-
icity data are available, one can hypothesize that the sub-
stance of interest has similar toxic potential. Read-across
can be both qualitative (substance X is a known skin sen-
sitizer, therefore very similar substance Y will also very
likely be a skin sensitizer) and quantitative (when the
potency or the effect dose is “read-across”). For the latter,
one assumes that the substance of interest has, for exam-
ple, a similar lowest observed adverse effect level
(LOAEL) as the laboratory-tested chemical having a
closely similar structure and/or functionality. If multiple,
sufficiently similar substances with toxicity data can be
identified, this will strengthen the accuracy of the read-
across (often termed a grouping or category approach). If
a trend is visible within the group, the read-across can be
refined by taking into account this trend (e.g., increasing
toxicity with increasing octanol–water partition
coefficient).
(Q)SAR/read-across methods are only as reliable as the
biological databases on which they are based. The most
extensive genetic toxicity databases are those which are
built on libraries of data from bacterial mutagenicity stud-
ies. Also, in vitro mammalian cell assay data collected
more than a few years ago employed test methods and
standards no longer seen as reliable for some assays. A
survey of pharmaceutical lead compounds found structur-
al determinants for clastogenicity due to non-covalent
DNA binding that interfere with topoisomerases [Snyder
et al., 2013], thus emphasizing the importance of includ-
ing models which extend beyond the domain of com-
pounds that are positive in bacterial mutagenicity assays.
Toxicokinetics
Absorption, distribution, metabolism, and elimination
(ADME) of a substance are key determinants of toxic
potential, including genomic damage. Absorption or bio-
availability determines systemic exposure upon exposure
of the organism to the substance under study. Tissue dis-
tribution of a substance and/or its metabolite(s) after
absorption is a result of multiple factors such as lipophi-
licity of the substance and rate and quantity of blood
flow to key organs and tissues. Metabolism or
biotransformation of a substance distributed to tissues
with xenobiotic metabolic capacity, such as the liver, may
lead to enhanced or decreased genomic damage due to
metabolic activation or detoxification, respectively. Elimi-
nation of a substance and its metabolites lowers body bur-
den of exposure via various routes including renal and
biliary excretion, perspiration, and respiration. Xenobiotic
metabolism represents a key elimination pathway (meta-
bolic clearance). Experimental evaluation of plasma phar-
macokinetics and metabolite identification, organ
distribution, and major route(s) of elimination with in
vivo studies allows for the generation of relevant data
with respect to systemic and organ exposure. While phar-
macokinetic data are routinely developed for pharmaceuti-
cals, they are often not available for chemicals being
developed for other purposes. Instead, physiologically
based pharmacokinetic (PBPK) modeling can be applied
for the prediction of in vivo internal doses. PBPK models
are built using limited or extensive ADME data, derived
from in vivo, in vitro, and/or in silico studies. They pro-
vide an estimation of internal exposure based on physico-
chemical data coupled with known physiological factors
such as route of exposure, blood flow, organ weight, and
xenobiotic metabolism pathways. PBPK can be used to
model various routes of exposure: dermal, oral, intrave-
nous, and inhalation, etc., coupled with exposure regimen
(single dose; multiple doses; continuous exposure) to esti-
mate exposure levels in various organs [Chetty et al.,
2014]. In some instances, the estimated exposure levels in
each tissue can be used, in combination with in silico/in
vitro findings, to predict in vivo genomic damage. Incor-
poration of xenobiotic metabolism and carrier-mediated
uptake and efflux transport in conjunction with known
population-based variations in these parameters can pro-
vide population specific pharmacokinetic parameters,
allowing prediction of population-specific effects.
PBPK models vary highly in complexity and in the
requirements for data that are used as input. Consequent-
ly, the predictions generated by these models may differ
greatly in level of uncertainty. Some circumstances may
require a higher level of confidence and thus more
detailed ADME data. For such purposes, short-term in
vivo studies with small numbers of animals could be per-
formed. An advantage of generating in vivo metabolism
data during pharmacokinetic studies is that information
on other tissues besides the liver can be collected. Liver
is considered the site of initial metabolism for most
ingested substances, but the gut microflora and intestinal
walls are also metabolically competent. In addition, there
are unique metabolic capabilities in a variety of tissues
including lung, kidney, gonads, and other hormone-
producing organs such as thyroid and adrenal glands; thus
ADME studies can be an important source of information
regarding the target tissue(s) of a particular substance.
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A recognized need for future testing is the incorpora-
tion of human-specific metabolism. Xenobiotic metabo-
lism may lead to activation as well as inactivation of
chemical substances. The current practice of using
induced rat liver S9 for in vitro studies may be limited in
certain instances due to species differences in xenobiotic
metabolism. Species differences in drug metabolizing
enzyme pathways are well established. For example, of
the major P450 isoform subfamilies involved in drug
metabolism, species differences in isoforms are observed
for CYP2B, CYP2C, CYP2D, and CYP3A. Pathway dif-
ferences can lead to species differences in rate of metabo-
lism, identity of metabolites, and associated toxic effects
[Lewis et al., 1998]. Estimation of human genomic dam-
age based on in vitro or in vivo data may result in a mis-
leading conclusion if, for example, human-specific
metabolism is a key determinant of genomic damage for
the substance in question. Particularly in these cases, use
of test systems incorporating (some aspects of) human
metabolism should be considered.
Mode of Action Information and Human Relevance
Mechanistic understanding of biological pathways
involved in toxicity is essential for a next generation
strategy to assess genomic damage and its relevance to
humans. Several conceptual frameworks on understanding
mode of action (MOA) have been published. The most
widely-known is the Mode of Action/Human Relevance
Framework (HRF) developed by the International Pro-
gramme on Chemical Safety (IPCS) from the World
Health Organization (WHO) and the ILSI Risk Sciences
Institute (ILSI RSI) [Boobis et al., 2006, 2008]. The HRF
has been updated recently and now also considers dose-
response relationships and species concordance in weight-
of-evidence analysis of hypothesized mode(s) of action
(MOA(s)) for critical effects and their qualitative and/or
quantitative relevance to humans [Meek et al., 2014]. The
Quantitative Key Events/Dose-Response Framework (Q-
KEDRF) from ILSI HESI’s RISK21 project [Simon et al.,
2014] builds upon both the HRF and the earlier Key
Events/Dose-Response Framework (KEDRF) [Julien
et al., 2009]. It provides a structured approach for under-
standing of the dose-response and temporal relationships
between the various key events (KEs) and the adverse
outcome as well as between the KEs themselves. For this,
two additional concepts are introduced: associative events
(AEs) and modulating factors (ModFs) [Simon et al.,
2014]. AEs can be considered as biomarkers for KEs,
whereas ModFs affect the timing and/or dose-response of
KEs. Life stage, disease state, genetics, lifestyle, and oth-
er factors underlie inter- and intra-individual variability in
the nature and strength of ModFs.
Understanding MOA is closely linked to the growing
use of adverse outcome pathways (AOPs); MOA and
AOP are similar, but distinct. Both can be described as a
series of KEs at different levels of biological organization
(e.g., molecular, subcellular, cellular, tissue, organism)
that result in a pathological or other disease outcome(s)
[Ankley et al., 2010 for review; OECD, 2013]. While the
AOP is ideally chemical-agnostic, a MOA is chemical-
(or agent-) specific. The MOA includes exposure and
metabolism, while an AOP starts with the initial molecu-
lar interaction following any necessary metabolism. In
addition, the term MOA, however, does not necessarily
imply adversity [Meek et al., 2014]. An example of an
application of the AOP concept for germ cell genomic
damage is provided for DNA alkylation [Yauk et al.,
2015b]. The AOP concept is highly valuable when
designing a new strategy as it provides structure and ter-
minology for organizing toxicological understanding
across different levels of biological organization. It also
offers a framework for integrating in silico models and in
vitro data and in vivo bioassays for toxicity testing.
Understanding of the MOA is then essential to link
together the observations made in the various assays.
Germ Cell Testing
Much discussion has centered on the concern for geno-
mic damage to the germ cells and the possible resultant
heritable risk for an organism. An IWGT workshop exam-
ined this issue and provided some key outcomes that
need to be considered when formulating risk management
questions and developing a testing strategy that incorpo-
rates assessment of potential germ cell damage [Yauk
et al., 2015a]. Among the major outcomes, it was
highlighted that available data suggest that somatic cell
tests can detect most germ cell mutagens, but there are
strong concerns that suggest caution in drawing conclu-
sions about potential germ cell susceptibility based solely
on data from somatic cells. When questioning whether
germ cell testing should be conducted, one consideration
suggests that if a substance or its metabolite(s) will not
reach target germ cells or gonadal tissue, it is not neces-
sary to conduct germ cell tests, notwithstanding the
somatic outcomes. Further, it was recommended that neg-
ative somatic cell mutagens with clear evidence for
gonadal exposure and evidence of toxicity in germ cells
could be considered for germ cell mutagenicity testing.
For characterizing risk of somatic mutagens that are
known to reach the gonadal compartments and expose
germ cells, the substance could be assumed to be a germ
cell mutagen without further testing. However, if a quan-
titative analysis is needed to estimate germ cell risk,
germ cell testing would provide the type of data that
would be needed.
At the IWGT workshop, the working group recognized
that possible insights regarding germ cell risk can be
obtained from other toxicity tests. Specifically, standard
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reproductive toxicology tests (e.g., one-generation and
multi-generational reproductive toxicology tests) and
repeat dose toxicity studies may provide signals pertinent
to germ cell genotoxicity, and are an important source of
information relating to potential germ cell hazards [ICH,
2005]. These assays capture important developmental
stages (e.g., in utero exposure, most of spermatogenesis)
that are not assessed using standard genetic toxicology
approaches and provide a wealth of information on repro-
ductive endpoints that can indicate both delivery of the
agent to male and female germ cells and gonadal tissues,
as well as cytotoxic effects that may occur following
exposure to genotoxicants. In addition, conduct of full
pathology on reproductive tissues is considered a very
sensitive method to identify effects. For example, evi-
dence of reduced testis weight and sperm count, increased
implantation loss and post implantation loss, and fetal
developmental abnormalities may be indicative of a possi-
ble genotoxic mechanism. A critical question relates to
whether adverse reproductive endpoints in humans, which
are found in 4% of live births, are related to genetic
(germ cell) damage, epigenetic effects, or non-genetic
developmental outcomes. The vast majority of adverse
human birth outcomes are inherited or caused by non-
disjunction events in aging ova, but most of these can be
quite readily removed from consideration when evidence
for genomic (and now more recently epigenetic) damage
is sought [Elespuru, 2011].
Integration of germ cell tests with routine somatic cell
testing was encouraged at the workshop. For instance, the
Globally Harmonized System of Classification and Label-
ling of Chemicals (GHS) provides a hazard categorization
for germ cell mutagenicity, thus emphasizing the impor-
tance of this endpoint [UNECE, 2015]. OECD established
guidelines for a few germ cell tests that can be considered
as part of a testing strategy, particularly for transgenic
rodent mutation models, aberration analysis in spermato-
gonia, and the dominant lethal test [OECD, 2015].
Though other germ cell tests do not have internationally
harmonized guidelines and currently have limitations,
implementation of other sperm assays that assess genomic
integrity, such as the TUNEL (terminal deoxynucleotidyl
transferase dUTP nick end labeling) and SCSA (sperm
chromatin condensation) assays are promising test sys-
tems. Whole genome sequencing is particularly empha-
sized as a powerful approach to determine mutational
spectra, to give insight to germ cell specific mechanisms,
and to quantify induced heritable mutagenesis. Sequenc-
ing can also help determine if a “weak” response in a
mutation assay may be biologically relevant or not. It was
noted, as described above, that limited types of genomic
damage are assessed using current germ cell approaches.
It was emphasized that assays to address newly emerging
genomic endpoints, such as copy number variants
(CNVs), were urgently needed.
Epigenetics
Many in the toxicology field propose expanding consid-
eration of genomic damage to include epigenetic mutations.
Epigenetic mutations, also called “epimutations,” can be
defined as persistent changes in gene activity and expres-
sion that occur, unlike genetic mutations, without a change
in the nuclear DNA sequence. Epimutations also include
persistent changes in chromatin (DNA methylation and/or
histone modifications) and non-coding RNAs, including
microRNAs. The increasing understanding of a multitude
of additional factors within the cell that exert a significant
amount of control over the ultimate output of the genome
has resulted in the creation of the field of epigenetics. With-
in the last decade, epigenetics has expanded from a niche
within genetics, to an established discipline that plays
important roles in basic biology, as well as applied human
health. Two aspects connecting epigenetic changes and
human health outcomes include evidence that substances
cause measurable and reproducible changes in epigenetic
patterns [Thomson et al., 2014; Zang and Peng, 2015] and
that epigenetic alterations are important factors in tumor
development and other human health outcomes [Chi et al.,
2010; You and Jones, 2012].
In addition to its position within basic science, there is an
emerging role of epigenetics in the fields of risk assessment
and genetic toxicology. However, at present there is insuffi-
cient knowledge to determine how epigenetics information
can contribute to toxicology and risk assessment, and how
to integrate it into a structured safety program [Goodman
et al., 2010]. The important issue that first must be
addressed is the need to understand normal variation and
influence of epigenetic markers in an unperturbed system
[LeBaron et al., 2010; Rasoulpour et al., 2011]. This high-
lights the critical need for a well-informed base of compari-
son if the impact of epigenetic changes due to specific
exposures is to be appropriately interpreted. Similar con-
cerns have been raised in terms of the recognized impor-
tance of epigenetics in pharmaceutical safety studies. A
possible testing paradigm was described as a means to
examine the feasibility of incorporation of epigenetic end-
points into a larger toxicology testing strategy [Priestley
et al., 2012 ]. Recently, special issues of (i) Mutation
Research/Genetic Toxicology and Environmental Mutagen-
esis [“Epigenetics and Chemical Safety”; Volumes 764–
765, 2014] and (ii) Environmental and Molecular Mutagen-
esis [Volume 55(3), 2014] focused on the impact of envi-
ronmental exposures on the epigenome. Among the
contributions, advancements in the understanding of epige-
netic markers were discussed [Thomson et al., 2014],
though this information was described in the context of car-
cinogenesis, and specifically the potential mechanisms of
non-genotoxic carcinogens.
The challenges mentioned above and the continued
efforts by many laboratories worldwide to further the
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knowledge of epigenetics serves to reinforce the desire to
apply what is known to regulatory safety programs and
human health risk assessment in a rational and well
thought-out manner. Though there are obvious links
between the fields of genetic toxicology and epigenetics,
the current level of understanding does not yet enable a
formally prescribed integration of the two and makes it
difficult to address epigenetics in a testing strategy at this
time. The stated need for more information on normal
variation across the multitudes of available markers only
serves to reinforce this perspective. As the current risk
assessment strategy improves and as the basic biology of
epigenetics is better defined, epigenetics should be kept in
mind and relevant data added to the knowledge base
where feasible in order to produce more useful and effec-
tive outcomes for risk assessment and human safety. As a
result, the testing strategy described here will not specifi-
cally address epigenetics, though enough flexibility exists
such that epigenetics can certainly be considered, again
where feasible and where appropriate tests have been
devised.
Create Rational Biological Argument
Using the knowledge base and the focus provided by
the planning and scoping process, a rational biological
argument for deciding the direction of testing can be put
forward. The process for building the argument is similar
to thinking described in an earlier HESI workgroup prod-
uct [Dearfield et al., 2011]. The process applies the
knowledge base created, and considers the data gaps that
need to be addressed, to identify the specific tests and
assay targets that are the most appropriate to assess
potential genomic damage. For example, MOA/AOP
information is used to identify potential key events and
the associated assays to be used to detect them. Use of
structural analogues and read-across considerations can
point to appropriate testing approaches for that type of
substance. The purpose of the biological argument then is
to identify the tests that are most likely and relevant, to
determine any potential for induction of genomic damage
by that substance.
When creating the specific biological argument for
what testing to pursue, the risk management questions
and the extent of the knowledge base will help determine
the amount of testing needed. Categorization of exposure
scenarios (see Table I) can help inform how to proceed.
The biological argument then needs to determine how
much concern the substance may present to exposed peo-
ple. Since the most basic question centers on whether the
substance has the capability or not to induce genomic
damage, some minimal amount of information/data is
necessary to provide some indication of this capability,
regardless of the level of concern the substance ultimately
may have. Based on the risk management question(s)
from planning and scoping and the information from this
minimal information/data set, the decision for additional
testing or not can be made.
The determination of a level of concern to attach to a sub-
stance relies on several factors that will likely be unique to
each substance, or class of substances, and perhaps in other
instances, mixtures of substances. The extent of potential or
projected exposure to humans is a primary factor. As more
exposure (as discussed above) is anticipated, the level of
concern rises and the argument focuses on what additional
testing beyond the minimal set is needed. Associated with
the extent of exposure is the question of whether the expo-
sure to the substance is intentional or not. If exposure to a
substance is intentional such as for a pharmaceutical, pesti-
cide, or food, then testing beyond the minimal set is likely
needed, and even more likely as the projected number of
people who will be (or are) exposed increases. For uninten-
tional exposures, such as accidents or environmental con-
taminants, a different level of concern will be applied
depending on the extent of exposure (number of people)
and what subgroups of the population may be exposed (e.g.,
susceptible groups). The amount and types of testing being
considered will obviously be different with the different
scenarios (e.g., if only concerned about accidental high
exposures producing a genomic effect, then testing at a limit
dose/concentration would be part of the rationale). Further
thinking should extend to consideration of possible genomic
damage as it relates to heritable effects in offspring and
future generations; this may heighten the level of concern
and may call for testing of germ cell related targets. The
projected or possible route of exposure will also inform
what types of tests will be useful (e.g., dermal exposure ver-
sus inhalation versus oral ingestion).
While creating the argument for what tests to conduct,
greater weight should be given to consideration of end-
points of genomic damage associated with human disease,
especially since human risk is being evaluated [MacGre-
gor et al., 2015b]. Furthermore, the genomic endpoint(s)
should be consistent with those identified as key events in
an AOP leading from the molecular initiating event to
disease [Yauk et al., 2013, 2015b; MacGregor et al.,
2015b]. A Quantitative Key Events/Dose-Response
Framework (Q-KEDRF) provides a useful structured
quantitative approach and guidance for a systematic
examination of the dose response and timing of KEs
resulting from a dose of a substance that potentially can
induce genomic damage [Simon et al., 2014].
Where possible, this approach will be employed in the
case studies that will be conducted to further delineate a
next generation strategy for genomic damage.
Select Assays and Perform Them
Ideally, the assays selected for testing will specifically
address the types of genomic damage of concern, e.g.,
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pertinent to the likely mode(s) of action described in the
biological argument. The number of assays selected can
range from a few tests to several tests. The testing strate-
gy may include other types of toxicity testing (e.g., devel-
opmental/reproductive toxicity testing) that could provide
insights about possible adverse genetic outcomes. The
testing will likely be conducted first with in silico meth-
ods and in vitro tests (including high-throughput tests),
but can include in vivo animal tests as the need arises
[see Thomas et al., 2013 for discussion of such an
approach]. An understanding of newer testing approaches
can be informative in the selection of the assays to use
[Zeiger et al., 2015].
OECD testing guidelines exist for users to follow to
ensure consistency, reliability, and reproducibility of
results destined to support regulatory purposes [OECD,
2015]. These guidelines describe the minimal protocol
and test information needed for an acceptable test. The
reliance on OECD testing guidelines has been, and con-
tinues to be, a great service to the regulatory testing com-
munity. However, the OECD guidelines have been
developed only for the tests most widely used and those
required by regulatory guidance. The universe of these
guidelines is becoming very small compared to the multi-
tude of assays now available to examine all sorts of toxic-
ity pathways and health-related endpoints—assays that
can be very useful for assessing genomic damage in its
many forms.
It is clear that tests without OECD guidelines will be
conducted (and needed) and the test universe will be
expanding rapidly (e.g., high-throughput tests, molecular-
based tests). Development of OECD guidelines for all
these tests will be difficult if not prohibitive. A critical
concern related to the use of newly developed, non-
guideline assays is their validity, that is, their reliability
(reproducibility) and relevance for the particular effect
being measured [OECD, 2005]. This is particularly
important for methods that have not been extensively
used beyond the laboratory that developed the method or
for a method that the testing laboratory has no or minimal
experience using. OECD recognizes the situation and pro-
vides some general guidance on how to describe non-
guideline in vitro tests [OECD, 2014a]. This guidance
outlines the elements considered relevant for providing a
comprehensive description of an in vitro method to facili-
tate an assessment of the quality of data produced and its
potential utility in regulatory applications. Confidence in
particular tests will come with increasing and broader use
and repetition from competent laboratories, and from peer
review.
Minimal Information/Data Set
Regardless of the concern level for any substance, a
minimal amount of information is necessary to determine
what decisions regarding genomic damage can be made.
At the very least, this information should clarify whether
there is the potential for genomic damage that requires
further testing to address. To collect this minimal infor-
mation/data set, a starting point would be to use in silico
methods (e.g., QSAR, computational methods) and high-
throughput assays that can provide a broad coverage of
potential toxicity pathways. This approach, wherein high-
throughput data from in vitro assays or small organisms
is combined with comprehensive and robust computation-
al methods to predict toxicity, has demonstrated its use-
fulness, e.g., [Liu et al., 2015]. For genomic damage,
MOA underlying “traditional” genetic toxicity endpoints
as well as MOA that are not associated with direct DNA
damage but known or hypothesized to be involved in
genomic damage, e.g., oxidative damage, enzyme inhibi-
tors, anti-metabolites, activation of transposable elements,
should be covered. These early predictive methods and
assays provide initial results, but also insight as to wheth-
er the biological argument initially constructed is still fea-
sible, or whether an alternative argument needs to be
considered.
The results from a minimal set of information/tests can
lead to a presumption of hazard (and possibly an estima-
tion of risk if the test results are amenable) and provide
input to the risk management decision among the follow-
ing options: (i) commit to additional testing if results are
positive, (ii) discontinue testing in order to initiate mitiga-
tion(s) if positive, or (iii) stop any further work if nega-
tive. These decisions also take into account the initial
exposure scenario—if minimal and/or low exposure is
expected or seen, then the decision to bring the testing to
a close is more likely; whereas, if high and/or widespread
exposure is expected, additional testing is likely even in
the case of an initial negative result (unless circumstances
dictate immediate action as in an emergency exposure
situation).
Additional Testing
Testing beyond the minimal test set may be necessary
under several scenarios. For the most part, results from
any additional tests, in concert with the minimal test
results, should be sufficient to provide input into the risk
estimates needed to address the risk management ques-
tions posed. The direction that additional testing would
take depends on what the circumstances dictate, such as
positive results from the initial test set that need clarifica-
tion or supporting evidence, or if the projected exposure
scenario shows extensive human exposure.
When positive results are found from the minimal test
set and additional testing is indicated, for whatever rea-
son, the guidance provided in an earlier ILSI HESI
GTTC work product is instructive [Dearfield et al., 2011].
Based on the nature of the substance’s structure and the
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genomic damage seen, and the information on the poten-
tial mode of action, the specific additional tests can be
identified (e.g., an assay for a particular event along a
toxicity pathway). From the initial tests, if known toxicity
pathways are implicated, an understanding could be
reached that certain tests can be utilized for evaluating
that pathway, thus providing a consistent selection of
appropriate additional tests. In a sense, this creates a
“network” pattern of test selection for decision flow.
We envisage that additional testing may also comprise
whole genome sequencing. The use of whole genome
sequencing is rapidly expanding to help determine geno-
mic damage in humans and animals and these approaches
are now being incorporated into testing for genomic alter-
ations. It has been shown recently that a typical human
genome contains on average about 100 loss-of-function
variants, and as many as 20 complete loss-of-function
mutations [MacArthur et al., 2012]. However, thus far
there are no data on how specific substance exposures
may impact the mutational load in the genome. Next gen-
eration sequencing technologies are now mature and cost
effective enough to be applied to identify intrinsic and
extrinsic variables that can affect genomic damage. A
recent proof of concept for the application of whole-
genome approaches in genetic toxicology was described
where array comparative genome hybridization and whole
genome sequencing in mice were used to produce a
genome-wide survey of induced mutations following
paternal exposure to ionizing radiation [Adewoye et al.,
2015]. Significant increases in copy number variants
indels, and multi-site mutations were found in the
descendants of irradiated fathers, demonstrating the prac-
tical application of these technologies for assessment of
heritable mutations. The study suggests that use of whole
genome sequencing methods can be very useful in exam-
ining genomic damage and should be considered when
delineating a specific strategy for a substance of concern.
When considering additional in vivo studies, the possi-
bility of “piggy-backing” genomic damage endpoints onto
existing in vivo protocols (e.g., subchronic toxicity stud-
ies, two-generation reproductive toxicity studies, extended
one-generation reproductive toxicity studies) should be
examined (also ensure that the combination assay does
not compromise the genomic damage component). These
in vivo assays could be further combined with whole
genome sequencing techniques to examine potential geno-
mic damage at the molecular level and provide further
detailed information regarding the sequence elements that
may be subject to alteration by the specific exposure.
Integrated animal testing, for example with multi-tissue
transcriptome analysis for pathway perturbations, is also a
distinct possibility [Thomas et al., 2013] providing
whole-genome assessment of potential pathway perturba-
tions in any tissue. A further possibility is the use of tran-
scriptional signatures to predict toxicities and facilitate
chemical screening where, for example, a transcriptomic
biomarker, TGx-28.65, was shown be a possible biomark-
er of genotoxicity [Yauk et al., 2016].
Review Results
After the testing is completed, the results are reviewed
to assess whether there is a significant effect in any of
the tests for genomic damage. These results are then fur-
ther analyzed for relevance for human adverse outcomes.
It should be noted that cancer is not the only adverse out-
come of concern for humans. All possible consequences
of genomic damage in humans should be considered. This
is important for characterizing the risk (see later).
The review should consider the distinction between sta-
tistical significance and biological significance. Assay
protocols usually have guidance as to what makes for a
statistical increase in effect over controls (or background)
and the increases need the usual analysis. But in addition,
the biological relevance of any indicated induction of
genomic damage should be scrutinized as well and char-
acterized as to being relevant or not for any adverse out-
come. It is becoming evident that in some cases assay
systems are providing greater sampling power (e.g., flow-
cytometric techniques) and are able to distinguish very
small increases as statistically significant—it is therefore
appropriate to address whether such very small increases
are also considered as biologically significant.
Another important conclusion is to ascertain the useful-
ness of the dose-response function for further quantitative
analysis (next section). The study design, developed prior
to testing, will determine the number and spread of the
concentrations or doses used. This should be planned to
provide data that are suited for quantitative dose-response
analysis. This will also help with describing any uncer-
tainties and possible variation that might be associated
with the data. Increasingly, approaches for extrapolating
in vitro concentrations to likely human doses (in vitro to
in vivo extrapolation (IVIVE) approaches) are being con-
sidered to compare in vivo dosage at probable/possible
target(s) in exposed persons [e.g., Embry et al., 2014; Pat-
lewicz et al., 2015]. This may potentially alleviate the
need for in vivo testing if the in vitro results can provide
meaningful data to extrapolate to predicted human
response outcomes for decision makers to consider.
Ultimately, the results need to be reviewed for consis-
tency with the proposed mode of action and whether they
are of concern for human adverse outcomes. If the test
results do not contribute to this understanding, analysis is
needed regarding why not, and whether another biological
argument needs to be created and a different testing
approach be pursued. The process may require revisiting
the original risk management questions and reviewing/
revising the original upfront planning and scoping
decisions.
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Select Appropriate Points of Departure (Dose-Response
Modeling)
Genetic toxicity testing has usually been performed at
relatively high concentrations for in vitro studies and high
(e.g., maximum tolerated dose (MTD)) doses for in vivo
studies. This was consistent with the hazard identification
approach for addressing whether the substance in question
had genomic damaging capability or not. In order to
achieve a better understanding of a substance’s potential
risk to exposed persons, a more detailed dose-response
analysis is needed. In some instances, the dose-response
curve, with supporting mode of action information, will
indicate a linear relationship. In these cases, the estima-
tion of potential adverse effects (i.e., genomic damage)
can be “read” directly from the dose-response curve.
However, in many other cases a non-linear dose response
will be observed and, for the most part, an approach to
extrapolate from higher testing doses to lower doses con-
sistent with human exposures will concentrate on selec-
tion of a PoD for the extrapolation.
After review of the data, and if the testing and the data
are deemed appropriate, a quantitative analysis of the
dose-response data can be conducted. Another GTTC
work group previously provided guidance for the use of
appropriate quantitative approaches for dose-response
modeling for well-known genetic toxicity endpoints [Gol-
lapudi et al., 2013; Johnson et al., 2014]. This guidance
should be incorporated into the study design and the
quantitative analysis. The major outcome of such dose-
response modeling is the ability to determine a PoD from
the observable effect range of the tested dose-response
curve for extrapolation to lower expected and/or anticipat-
ed human exposures. This emphasis on the usefulness of
the PoD approach was reinforced by expert discussions at
the IWGT [MacGregor et al., 2015a].
These collective efforts examined several quantitative
analysis approaches in common use for other toxicity
endpoints for adaptability to genetic toxicity testing
results. These included: (i) the no-observed-genotoxic-
effect-level (NOGEL), which is the genotoxicity endpoint
equivalent of the no-observed-effect-level (NOEL) used
in toxicology; (ii) the benchmark dose (BMD), or bench-
mark concentration (BMC), which is the dose or concen-
tration where a defined response, or benchmark response
(BMR), is observed; and (iii) a statistically defined break-
point analysis, referred to as the breakpoint dose (BPD),
which is determined using a bi-linear dose-response mod-
el. For fuller descriptions of these approaches to quantita-
tively assess the results from genetic toxicity tests and
how to apply them, see the publications from these work-
ing groups [Gollapudi et al., 2013; Johnson et al., 2014;
MacGregor et al., 2015a; also, see Johnson et al., 2015].
Based on the strengths and weaknesses of each of these
approaches, it was concluded that the order of preference
for deriving the PoD is: BMDL>NOGEL>BPDL. The
BMDL was determined to be the most robust and conser-
vative and is recommended for general use as the PoD
for genetic toxicity testing analysis [Gollapudi et al.,
2013; MacGregor et al., 2015a]. Since BMD has proven
its usefulness for other toxicity endpoints as well, we
here propose to use the BMDL approach to determine the
PoD (or PoDs) for estimating potential human risks asso-
ciated with genomic damage.
Determine Expected/Anticipated Exposures
The primary purpose of an exposure assessment is to
estimate dose to exposed persons, which is combined
with chemical-specific dose-response data (usually from
animal studies) in order to estimate risk [USEPA, 1992].
During the planning and scoping stage, the expected and/
or anticipated human exposures to the substance(s) of
interest have been identified. These initial findings help
determine whether there are any possible exposures, pro-
jected routes, and sources of exposure, and whether the
potential exposures provide enough concern to move for-
ward with genetic toxicity testing. Once a decision is
made to perform such testing, these initial findings no
longer suffice. At this stage, an exposure assessment
should also be planned.
While the testing of the substance in question is being
conducted, an exposure assessment to estimate the likely
human exposure can be concurrently developed. Exposure
scenarios are modeled with the use of expected or default
exposure factors [e.g., USEPA, 2011a; CDC, 2014].
These estimates are important for helping determine the
extent of the risk to the population or subgroup of the
population identified in the planning and scoping stage.
Depending on the purpose of the risk assessment, the
exposure assessment may need to emphasize certain areas
in addition to quantification of exposure and dose, for
example, the number of people exposed and the duration
and frequency of exposure(s). Within the ILSI HESI
RISK21 project, a four-stage, tiered approach to estimat-
ing exposure was developed [Embry et al., 2014]. In this
approach, exposure estimates are constructed from infor-
mation that is increasingly data-rich, ranging from limited
information provided by physicochemical properties and
route of exposure information to data from human biomo-
nitoring studies [Embry et al., 2014]. The methodology
and guidance for exposure assessment is outside the scope
of this discussion. The reader is referred to more authori-
tative sources for the conduct of an exposure assessment
[e.g., USEPA, 1992; Embry et al., 2014].
Estimate Candidate Regulatory Levels for Endpoints of
Most Concern/Relevance
The PoDs from the testing data and the exposure esti-
mates are combined to ascertain the possible risk from
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any observed genomic damage. The two methods that
have been explored to provide an indication of risk from
potential genomic damage include the margin of exposure
(MOE) approach and the reference dose (RfD) approach
[Johnson et al., 2014; MacGregor et al., 2015b]. If a line-
ar dose-response relationship is determined from the data,
then the estimated risk can be “read” from the curve and
associated with the exposure assessment. However, the
MOE and RfD approaches will likely be utilized in most
instances to estimate a potential regulatory level.
The MOE approach is one that can easily be used
when examining genotoxicity data [EFSA, 2005].
Although originally proposed for genotoxic carcinogens,
the MOE approach is easily adapted to characterizing any
toxicity risk. The method, in which the PoD is compared
to the actual or predicted human exposure detailed from
the exposure assessment, is relatively straightforward. It
may be the preferred approach as it directly incorporates
estimated or actual human exposure information in the
calculation (i.e., it is a ratio of the PoD to human expo-
sure). The MOE does not actually provide a quantification
of risk, but does provide perspective on a level of possi-
ble concern for decision making based on the magnitude
of the ratio (see next section) [EFSA, 2005]. The MOE
approach for genome-damaging substances is demonstrat-
ed in associated publications [Johnson et al., 2014, 2015].
The RfD (and reference concentration (RfC)) approach
can provide quantitative information for use in risk
assessments [USEPA, 2002]. The RfD (expressed in units
of mg of substance/kg body weight per day) is defined as
an estimate (with uncertainty spanning perhaps an order
of magnitude) of a daily exposure to the human popula-
tion (including sensitive subgroups) that is likely to be
without an appreciable risk of deleterious effects during a
lifetime [USEPA, 2015]. An RfD is determined by apply-
ing uncertainty factors (UFs) to the selected PoD to
reflect and address limitations of the data, usually with
linear extrapolation to lower doses. The concatenated UFs
account for various sources of uncertainty. Typically, for
most non-cancer endpoints, a composite or total UF of
100 is often derived by multiplying a factor of 10 for ani-
mal to human extrapolation and a factor of 10 for vari-
ability within human populations. These UFs are often
default values, but can be adjusted if additional informa-
tion is available. Such information may include incorpora-
tion of actual exposure and pharmacokinetic/metabolism
characteristics, studies in multiple or more relevant ani-
mal species indicating an adjustment is appropriate, or
the identification of vulnerable human population sub-
groups that need increased protection [for fuller discus-
sion see USEPA, 2014b; MacGregor et al., 2015b].
Furthermore, chemical-specific adjustment factors
(CSAFs; also known as data-derived extrapolation factors
(DDEFs) for interspecies and intraspecies extrapolation)
are sometimes available for interspecies differences and
human variability and can be used in place of correspond-
ing default UFs [WHO/IPCS, 2005; USEPA, 2014b]. If
the dose-response analyses rely on animal-based studies
versus human-based studies, then an allometric scaling
(e.g., based on body weight3/4) needs to be calculated as
a basis for scaling toxicity data and values from animal
models to human equivalents for human health risk
assessments [see USEPA, 2011b for fuller discussion].
Risk Characterization
Risk characterization is a vital component of the risk
assessment process [NRC, 1983]. To determine risk, the
dose-response relationship for an identified hazard and
human exposure information are combined to provide an
estimate of potential harm to exposed persons. The character-
ization describes the findings of the testing and the implica-
tions those findings have on adverse health outcomes for
exposed people, in particular, the role the genomic damage
plays in human disease or adverse outcomes. The estimates
for the risk based on the endpoints of most concern or rele-
vance for humans are provided. The qualitative description
and the quantitative estimates provide the information need-
ed to address the goals and risk management questions posed
during the planning and scoping process [USEPA, 2000].
Among the qualitative discussion of the risk characteri-
zation, key findings, results, and decisions are highlighted
to support whether there is genotoxic risk to humans or
not. Key points to highlight would include: the selection
of appropriate genetic endpoints and target tissues, the
selection of uncertainty factors and extrapolation methods
used, the importance and use of information on MOA,
toxicokinetics, metabolism, and predicted exposure infor-
mation, including exposure biomarkers [taken from Mac-
Gregor et al., 2015b].
When considering the MOE approach for regulatory
decision making, and any discussion for risk management
interventions, the magnitude of the MOE ratio is evaluated
and characterized. A larger MOE would be of less concern
(e.g., MOE 10,000 may be considered to present minimal
risk), though it would not preclude risk managers taking
action to further reduce human exposure [EFSA, 2005]. A
smaller MOE is likely to be of greater concern (e.g.,
MOE< 100) and risk managers would want to consider
risk management options to increase the ratio (most often
by measures to reduce exposure). Other parameters for risk
managers to consider when regarding the magnitude of the
MOE include the severity of the effect, the MOA, the
number of adverse effects observed, whether the observed
effect(s) are from animal or human studies, the number of
assumptions used in MOE estimations, the size of the
affected population, and whether any susceptible subgroups
have been identified [taken from Johnson et al., 2014].
A useful presentation for risk managers to consider is
shown in Figure 3. Here the PoD is simply divided by
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the exposure estimate to calculate a margin of exposure
(MOE) metric. This provides one with an idea of the
magnitude of separation between a dose of the substance
and when to expect a possible adverse outcome due to
the genomic damage.
When considering the RfD approach for regulatory
decision making, the decision generally hinges upon what
uncertainty factors are applied to the PoD. The general
default combination of factors (composite UF) usually is
100 as described above. But there are many consider-
ations that need to be characterized to justify the use of
100, or to justify a different selection of uncertainty fac-
tors. These considerations include: species differences and
allometric scaling, differences in absorption, distribution,
metabolism and pharmacokinetics, differences in duration
and/or frequency of exposure, severity of toxicity end-
point, variability among individuals, and uncertainty in
the PoD [taken from MacGregor et al., 2015b]. When
data are absent that would address a particular factor
(e.g., differences in pharmacokinetics between tested ani-
mal species and humans), uncertainty factors should be
applied to the predicted acceptable exposure level to
account for the absence of data [USEPA, 2014b; MacGre-
gor et al., 2015b]. Historically, composite UFs have not
exceeded 3,000. Once the RfD is calculated, then risk
managers can make decisions regarding the magnitude of
genotoxic risk to exposed humans by comparing the
expected or calculated exposure to the RfD. Any risk mit-
igation actions can then be considered.
Ultimately, the genotoxicity testing results and risk
characterization should be evaluated against the goals and
risk management questions developed during the planning
and scoping. This will help focus the regulatory decision
making squarely on the human risk from genomic damage
and provide clear actions for reduction or elimination of
any risk that may have been identified.
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